Acupuncture for the treatment of marrow suppression after chemotherapy
A protocol for systematic review and meta-analysis
Guoyan Geng, MD, Zihan Yin, MM, Mingsheng Sun, PhD, Guixing Xu, MM, Jiao Chen, PhD, Fanrong Liang, PhD, Ling Zhao, PhD

Abstract
Background: Cancer continues to be a severe global health problem and the leading cause of death worldwide. Chemotherapy as the main treatment has various side effects, of which marrow suppression is the most common one. Acupuncture had shown clinical effects for marrow suppression after chemotherapy in many studies. However, the efficacy and safety of acupuncture therapy for marrow suppression after chemotherapy remains unclear.

Objective: This protocol aims to evaluate the efficacy and safety of acupuncture for marrow suppression after chemotherapy according to the existing randomized controlled trials.

Methods and analysis: The randomized controlled trials on acupuncture therapy for marrow suppression after chemotherapy will be searched in the database of Embase, PubMed and Cochrane Library, Allied and Complementary Medicine Database (AMED), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), WanFang Database (WF), and related registration platforms (WHO ICTRP, Clinical Trials, and Chinese Clinical Trial Register [ChiCTR]), Grey Literature Database from inception to 1 August 2020. The primary outcomes will be assessed using white blood cell (WBC) count, platelet count, hemoglobin count and the number of neutrophils (N). Review Manager V.5.3 software will be applied for statistical analyses. We will measure the risk of bias of the included studies with Cochrane Collaboration Risk of Bias Tool. Finally, Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) will be used to grade the overall quality of evidence. And we will use the intra-group correlation coefficient to assess the consistency of reviewers.

Result: This systematic review and meta-analysis will put a high-quality synthesis of the efficacy and safety of acupuncture treatment in marrow suppression after chemotherapy.

Conclusion: The conclusion of this systematic review will provide evidence to assess acupuncture therapy is an efficacy and safe intervention to treat and control marrow suppression after chemotherapy.

PROSPERO registration number: PROSPERO CRD42020163336
Abbreviations: RCT = randomized controlled trial, SR = systematic reviews.
Keywords: acupuncture, cancer, chemotherapy, marrow suppression, meta-analysis, protocol, systematic review

GG and ZY are the first co-authors to this paper.

This proposed systematic review and meta-analysis is based on published data, and thus there is no requirement for ethics approval. The findings of this study will be presented at conferences and disseminated through publication in a peer reviewed journal. We will modify this protocol if necessary in the future. The original protocol, the final protocol, and summary of changes will be supplemented.

This work is financially supported by the National key research and development program (no. 2019YFC1709700) and the National Natural Science Foundation of China (nos. 81590951, 81722050, 81973961). The authors have no conflicts of interest to disclose.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Correspondence: Fanrong Liang, Ling Zhao, Chengdu University of Traditional Chinese Medicine, 37 Shierqiao Road, Chengdu, China (e-mail: acuresearch@126.com, zhaoling@cdutcm.edu.cn).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Geng G, Yin Z, Sun M, Xu G, Chen J, Liang F, Zhao L. Acupuncture for the treatment of marrow suppression after chemotherapy: a protocol for systematic review and meta-analysis. Medicine 2020;99:34(e21876).

Received: 17 July 2020 / Accepted: 23 July 2020
http://dx.doi.org/10.1097/MD.00000000000021876
1. Introduction
Cancer is a major public health problem worldwide and is the leading cause of death.\textsuperscript{[1-2]} The lifetime probability of being diagnosed with invasive cancer is approximately 37.7% to 39.3%.\textsuperscript{[2]} Chemotherapy plays an important role in the treatment of cancer in clinical practice.\textsuperscript{[3-5]} As bone marrow is highly sensitive to chemotherapy, marrow suppression (manifested as leukopenia,\textsuperscript{[6]} thrombocytopenia,\textsuperscript{[7]} and anemia,\textsuperscript{[8]} etc) is a major concern in cancer chemotherapy. In addition, marrow suppression could cause fever, skin rash, bone pain, and other adverse reactions.\textsuperscript{[9]-\textsuperscript{11}} Furthermore, it may lead to treatment interruption or even death.\textsuperscript{[12,13]}

The main reason for marrow suppression is that chemotherapy cannot only attack tumor cells, but also inhibit the strong proliferation and low differentiation of bone marrow cells and suppress all immature cells with proliferative function, eventually leading to marrow suppression.\textsuperscript{[14]} Currently, treatment options for chemotherapy induced marrow suppression are mainly pharmacological interventions, with high cost and unsatisfactory efficacy, are not ideal.\textsuperscript{[15-17]} Therefore, management of chemotherapy induced marrow suppression is challenging patients, doctors, and health departments of governments. So it is urgent to seek a nonpharmacological intervention for chemotherapy induced marrow suppression. In eastern, acupuncture is an ancient nonpharmacological therapy for chemotherapy induced marrow suppression, with relatively low cost and fewer side effects.\textsuperscript{[18]} Furthermore, increasing clinical studies have shown that acupuncture has a good therapeutic effect for chemotherapy induced marrow suppression.\textsuperscript{[19-22]}

Based on these grounds, we have confused an important clinical question: Is acupuncture effective and safe for patients with marrow suppression after chemotherapy? Unfortunately, from the perspective of evidence-based medicine, the efficacy and safety of acupuncture for marrow suppression after chemotherapy is still unclear. Therefore, we have an opportunity to assess the issue and envision this systematic review to explore the efficacy and safety of acupuncture treatment for marrow suppression after chemotherapy.

2. Objectives
The purpose of this study is to assess the efficacy and safety of existing acupuncture methods in the treatment of marrow suppression after chemotherapy through systematic review and meta-analysis.

3. Methods
This systematic review (SR) will be conducted in accordance with the Cochrane Handbook for Intervention Reviews. Evaluation will be carried out following the items from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).\textsuperscript{[23]}

3.1. Patient and public involvement
The public or participants were not covered in the design of this protocol.

3.2. Eligibility criteria
3.2.1. Types of studies. All randomized controlled trial (RCTs) about acupuncture for marrow suppression after chemotherapy without language or publication type restriction. Nonrandomized clinical studies, quasi-RCTs, cluster RCTs, and case reports will be excluded.

3.2.2. Types of participants. Trials involving adult patients diagnosed with chemotherapy induced marrow suppression will be included. We will not enroll studies of participants with other specific diseases, and only extract data on adults with chemotherapy induced marrow suppression.

3.2.3. Types of intervention. Acupuncture treatments (manual acupuncture, electroacupuncture, ear acupuncture, warm needling, moxibustion, etc) as monotherapy or additional therapies regardless of stimulation methods and needling techniques will be included in intervention group. Acupuncture therapy combined with blood-letting therapy, cupping, herbal medicine, point injection, or laser acupuncture will be excluded.

3.2.4. Types of control group. Control group will cover conventional medicine, placebo group and sham acupuncture (nonacupoint, minimal), no treatment, usual care, and others. RCTs which compare different technologies/different acupoints will be excluded from our study.

3.2.5. Types of outcome measures. Studies reporting one or more of the following outcomes will be included.

3.2.5.1. Primary outcomes. The main objective of the SR is to evaluate the efficacy and safety of acupuncture for chemotherapy induced marrow suppression; therefore, the primary outcomes are as follows: white blood cell (WBC) counts,\textsuperscript{[24]} platelet counts,\textsuperscript{[25]} hemoglobin counts,\textsuperscript{[26]} or other validated outcome measures.

3.2.5.2. Secondary outcomes. The secondary outcomes include anxiety measured by Self-rating Anxiety Scale,\textsuperscript{[27]} Hamilton Anxiety Scale\textsuperscript{[28]} or others; depression evaluated by Self-rating Depression Scale,\textsuperscript{[29]} Hamilton Depression Scale\textsuperscript{[30]} and the like; quality of life measured by validated scales, like the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ),\textsuperscript{[31]} the Edmonton Symptom Assessment System,\textsuperscript{[32]} Karnofsky Performance Status score,\textsuperscript{[33]} adverse events related to acupuncture (such as nausea, fainting, hematoma, etc).

3.3. Search strategy
3.3.1. Electronic searches. From the inception dates to September 1, 2020, the following electronic databases will be searched: PubMed, Embase, Cochrane Library, Allied and Complementary Medicine Database (AMED), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), WanFang Database (WF).

3.3.2. Searching other resources. We will search clinical trial registries (WHO ICTRP, Clinical Trials, and Chinese Clinical Trial Register) and Grey Literature Database. Besides, the following journals in China will be searched: Acupuncture Research, Chinese Acupuncture and Moxibustion and Journal of Traditional Chinese Medicine. Additional trials will be further identified according to the list of all identified publications including relevant systematic reviews and meta-analyses.
3.3.3. Searching methods. Although the search methods of different databases are varied, the search terms are mainly composed of 3 parts:

1. clinical condition: cancer, chemotherapy, marrow suppression, etc;
2. acupuncture methods: acupuncture therapy, manual acupuncture, electroacupuncture, ear acupuncture, transcutaneous electrical nerve stimulation and the like;
3. study type is random controlled trial (RCT).

The searching strategy of PubMed is presented in Table 1, and the equivalent words will be used in other sources.

3.4. Data collection and analysis

3.4.1. Study selection. Two researchers (GG and MS) will have a professional training for this study. And we will conduct the intra-group correlation coefficient to evaluate the consistency between 2 reviewers. When selecting a study, firstly we need to read the title/abstract of the trial to remove duplicate cases and find eligible works. The search results will be uploaded through NoteExpress. GG and MS will independently select through screening the titles and abstracts. Any disagreements in research will be resolved through discussions by 2 reviewers (GG and MS). If they do not come to an agreement, the 3rd party (LZ or FL) will need to make the final decision.

3.4.2. Data extraction. Data extraction will be carried out independently by 2 reviewers (GG and MS) through a standard data extraction form. If there is a disagreement, it will be discussed and judged by the arbitrator (LZ). Two researchers will fill and crosscheck the message into Excel. We will use the inter-group correlation coefficient to assess the consistency of reviewers. General data for selected studies will be extracted, including first author, year of publication, country, age, gender, diagnostic criteria, sample size, treatment group, control group, acupoints, acupuncture details, outcome, conclusion, etc. We will show a Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA-P) flow chart (Fig. 1) to introduce the selection procedure.

3.4.3. Quality assessment. Two reviewers will independently assess the risk of bias with Cochrane Collaboration’s tool, which covers 7 domains: selection bias, performance bias, blinding of participants/personnel, blinding of outcome, attrition bias, reporting bias and other sources biases. It will be classified as “low risk of bias,” “unclear risk of bias” and “high risk of bias.” In case of disagreement, the arbiter (LZ or FL) shall be consulted. Graphic representations about risk of bias will be generated using Review Manager (RevMan) V.5.3.0.

3.4.4. Measures of treatment effect. For continuous data, the mean difference or standard mean difference will be calculated by risk ratio with 95% confidence intervals. For dichotomous data, the odds ratio will be used. In case of disagreement, the arbiter (LZ or FL) shall be consulted. Graphic representations about risk of bias will be generated using Review Manager (RevMan) V.5.3.0.

3.4.5. Dealing with missing data. When the data of articles are ambiguous or insufficient, we will contact the author to require original information through e-mail or telephone. If it is not available, the impact of missing data will be described and discussed in the study necessarily.

3.4.6. Data synthesis. The data will be conducted and synthesized by the RevMan V.5.3.0 from Cochrane Collaboration. We will choose the fixed effects model ($I^2 < 50\%$) or random effects model ($I^2 \geq 50\%$). The effect size with risk ratio will be suitable for dichotomous data, and the continuous data will be analyzed by mean difference or standard mean difference. When meta-analysis is not feasible, the results will be described narratively.

3.4.7. Assessment of heterogeneity. We will concentrate on details of patients, interventions, and outcomes to test heterogeneity. According to the Cochrane Handbook V.5.3.0, we will conduct the $I^2$ test or the tau$^2$ test to assess statistical heterogeneity in each analysis. It is premeditated that it is no heterogeneity between the RCTs when $P > .1$, $I^2 < 50\%$, and the

| Table 1 |
| Search strategy for the PubMed database. |
| #1 marrow suppression[Title/Abstract] |
| #2 Myelosuppression[Title/Abstract] |
| #3 chemotherapy[Title/Abstract] |
| #4 cancer[Title/Abstract] |
| #5 #1 OR #2 AND #3 AND #4 |
| #6 acupuncture therapy[Title/Abstract] |
| #7 acupuncture-moxibustion[Title/Abstract] |
| #8 meridian[Title/Abstract] |
| #9 electroacupuncture[Title/Abstract] |
| #10 #6 OR #7 OR #8 OR #9 |
| #11 acupuncture[Title/Abstract] |
| #12 acupuncture Points[Title/Abstract] |
| #13 acupuncture[Title/Abstract] |
| #14 acupuncture-acupuncture therapy[Title/Abstract] |
| #15 #11 OR #12 OR #13 OR #14 |
| #16 warm needling[Title/Abstract] |
| #17 moxa needle[Title/Abstract] |
| #18 acupuncture plus moxibustion[Title/Abstract] |
| #19 moxibustion with warming needle[Title/Abstract] |
| #20 #16 OR #17 OR #18 OR #19 |
| #21 auricular acupuncture[Title/Abstract] |
| #22 auricular needle[Title/Abstract] |
| #23 ear acupuncture[Title/Abstract] |
| #24 moxibustion[Title/Abstract] |
| #25 #21 OR #22 OR #23 OR #24 |
| #26 abdomen acupuncture[Title/Abstract] |
| #27 embedded thread therapy[Title/Abstract] |
| #28 embedding thread[Title/Abstract] |
| #29 catgut embedding[Title/Abstract] |
| #30 #26 OR #27 OR #28 OR #29 |
| #31 #10 OR #15 OR #20 OR #25 OR #30 |
| #32 #5 AND #31 |
| #33 Myelosuppression[MeSH Terms] |
| #34 Acupuncture therapy[MeSH Terms] |
| #35 (#5 OR #33) AND #34 |
| #36 #35 OR #32 |
| #37 clinical[Title/Abstract] |
| #38 trial[Title/Abstract] |
| #39 #37 AND #38 |
| #40 clinical trials as topic[MeSH Terms] |
| #41 clinical trial[Publication Type] |
| #42 random[Title/Abstract] |
| #43 random allocation[MeSH Terms] |
| #44 therapeutic use[MeSH Subheading] |
| #45 #39 OR #40 OR #41 OR #42 OR #43 OR #44 |
| #46 #45 AND #36 |
fixed effects model will be used for statistics. Otherwise, when \( P \leq 0.1, I^2 \geq 50\% \), we adopt random effects model to analyze.

3.4.8. Publication bias. If necessary, meta-regression will be performed to avoid publication bias and symmetry of the funnel plot will be used to assess publication bias across studies or selective reporting bias.

3.4.9. Subgroup analysis and sensitivity analysis. We will perform subgroup analysis based on characteristics of patients, acupuncture methods, outcomes and the like when a substantial heterogeneity is found. Statistical heterogeneity in the study will be quantitatively assessed by \( I^2 \). We will make a narrative comment to illustrate this point if the heterogeneity could not be found. If possible, we will perform a sensitivity analysis to test the robustness of the combined treatment effect. We will consider 2 factors: the effect of high risk of bias or unclear risk of bias, and the effect of the selected model. If inconsistent results are found, use caution when introducing the results and making conclusions.

3.4.10. Grading of quality of evidence. We will eliminate the quality of evidence through Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach.\(^{35,36}\) The GRADE will be carried out to evaluate the quality of evidences from five items limitation (risk of bias, inconsistency, indirectness, imprecision, and report bias) and additional fields where appropriate in it. And the evidence will be ranked as “high,” “moderate,” “low,” or “very low.”

3.4.11. Patient and public involvement. Nobody will be directly involved. Only data and the sources will be used for this SR.
4. Discussion

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) pointed out that after surgery or inoperable patients, chemotherapy are clearly listed as the first-line treatment strategy for many cancers due to the efficaciy.[17] However, chemotherapy cannot only attack tumor cells, but also inhibit the strong proliferation and low differentiation of bone marrow cells and suppress all immature cells with proliferative function, eventually leading to marrow suppression.[14]

In China, acupuncture plays an important role in the treatment of chemotherapy induced marrow suppression. However, no SR which is the key part of evidence integration[18] has confirmed that acupuncture is safe and effective in chemotherapy induced marrow suppression and the mechanism of acupuncture in the treatment of chemotherapy induced marrow suppression is complex and unclear. We urgently need to assess the efficacy and safety of acupuncture for chemotherapy induced marrow suppression through SR.

To the best of our knowledge, the study will be the first SR to investigate acupuncture treatment for chemotherapy induced marrow suppression. We expect that the review could provide a basis for acupuncture treatment for chemotherapy induced marrow suppression and offer more and better treatment options for patients. Based on clinical evidence of the SR, it may also provide new treatment options for doctors. However, there may be some limitations (different types of acupuncture, varied control group, lack of research, etc) in the SR, which may lead to potential heterogeneity. Necessarily, sensitivity analysis or subgroup analysis would be adopted to explain the heterogeneity.

Author contributions

Guoyan Geng and Zihan Yin contributed equally in this paper. Zihan Yin and Ling Zhao conceived this study. Guoyan Geng and Zihan Yin will develop the study protocol and will implement the systematic review under the supervision of Jiao Chen. Guixing Xu will provide the statistical analysis plan of the study and will conduct data analysis. Guoyan Geng and Mingsheng Sun will perform the study search, screening, and extraction of data whereas Fanrong Liang and Ling Zhao will review the work. Guoyan Geng and Zihan Yin wrote the first manuscript draft and all authors gave input to the final draft of the protocol.

References

[1] Paice JA. Cancer pain management and the opioid crisis in America: how to preserve hard-earned gains in improving the quality of cancer pain management. Cancer 2018;124:2491–7.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
[3] Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004;7:139–56.
[4] Petrelli F, Ghidini M, Barni S, et al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Gastric Cancer 2019;22:245–54.
[5] Liu W, Zhang CC, Li K. Prognostic value of chemotherapy-induced leukopenia in small-cell lung cancer. Cancer Biol Med 2013;10:92–8.
[6] La Nasa M, Gaughan J, Cardonick E. Incidence of neonatal neutropenia and leukopenia after in utero exposure to chemotherapy for maternal cancer. Am J Clin Oncol 2019;42:351–4.
[7] Hakeem HA, Arab A, Azzam A, et al. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC). Cancer Chemother Pharmacol 2018;81:697–704.
[8] Rodgers GM, Gilreath JA. The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy. Acta Haematol 2019;142:13–20.
[9] Kadakia MP. Human herpesvirus 6 infection and associated pathogenesis following bone marrow transplantation. Leuk Lymphoma 1998;31:251–66.
[10] Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis 2014;59:106–14.
[11] Zeng SY, Li L, Zhong ML, et al. A randomized controlled trial of two chemotherapy regimens (paclitaxel liposome combined with platinum and paclitaxel combined with platinum) in concurrent chemotherotherapy for cervical carcinoma. Chin J Oncol 2011;33:517–9.
[12] Nian J, Sun X, Guo J, et al. Efficacy and safety of acupuncture for chemotherapy-induced leukopenia: protocol for a systematic review. BMJ Open 2016;6:e010787.
[13] Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005;23:6908–18.
[14] Yamashina T, Baghdadi M, Yoneda A, et al. Cancer stem-like cells derived from chemotherapy-resistant tumors have a unique capacity to prime tumorigenic myeloid cells. Cancer Res 2014;74:2698–709.
[15] Gardner RV, Lerner C, Astle CM, et al. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol 1993;32:2450–4.
[16] Hu Y, Cai ZQ, Su XY. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer: a meta-analysis result. Asian Pac J Cancer Prev 2012;13:4301–4.
[17] Shi X, Yang SF, Chen MH, et al. Significant effect of acupuncture in elevating blood stem cell factor during chemotherapy in patients with gynecologic cancer. J Nurs Res 2018;26:411–9.
[18] Fu H, Chen B, Hong S, et al. Acupuncture therapy for the treatment of myelosuppression after chemotherapy: a literature review over the past 10 years. J Acupunct Meridian Stud 2015;8:812–6.
[19] Zhang HW, Lin ZX, Cheung F, et al. Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer. Cochrane Database Syst Rev 2018;11:CD010559.
[20] Cybulzar PA, Brothers K, Singh GM, et al. The safety of acupuncture in patients with cancer therapy-related thrombocytopenia. Med Acupunct 2015;27:224–9.
[21] Choi TY, Lee MS, Ernst E. Moxibustion for the treatment of chemotherapy-induced leukopenia: a systematic review of randomized clinical trials. Support Care Cancer 2015;23:1819–26.
[22] Ladas EJ, Rooney D, Taromina K, et al. The safety of acupuncture in children and adolescents with cancer therapy-related thrombocytopenia. Support Care Cancer 2010;18:1487–90.
[23] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
[24] Hou L, Gu F, Gao G, et al. Transcutaneous electrical acupoint stimulation (TEAS) ameliorates chemotherapy-induced bone marrow suppression in lung cancer patients. J Thorac Dis 2017;9:809–17.
[25] Isoardi KZ, Harris K, Carmichael KE, et al. Acute bone marrow suppression and gastrointestinal toxicity following acute oral methotrexate overdose. Clin Toxicol (Philadelpa, Pa) 2018;56:1204–6.
[26] Zong-Wen S, Shuang-Yan Y, Feng-Lei D, et al. Radiotherapy for adult medulloblastoma: evaluation of helical tomotherapy, volumetric intensity modulated arc therapy, and three-dimensional conformal radiotherapy and the results of helical tomotherapy tomotherapy. BioMed Res Int 2018;2018:9153496.
[27] Li X, Zhu J, Li P, et al. A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain. Chin J Cancer Res 2014;26:174–82.
[28] Li XJ, Dai ZY, Zhu BY, et al. Effects of sertraline on executive function following functional magnetic resonance imaging fMRI-activation modulated arc therapy, and three-dimensional conformal radiotherapy and the results of helical tomotherapy tomotherapy. BioMed Res Int 2018;2018:9153496.
[29] Li X, Zhu J, Li P, et al. A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain. Chin J Cancer Res 2014;26:174–82.
[30] Li XJ, Dai ZY, Zhu BY, et al. Effects of sertraline on executive function following functional magnetic resonance imaging fMRI-activation modulated arc therapy, and three-dimensional conformal radiotherapy and the results of helical tomotherapy tomotherapy. BioMed Res Int 2018;2018:9153496.
[31] Li X, Zhu J, Li P, et al. A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain. Chin J Cancer Res 2014;26:174–82.
[32] Li XJ, Dai ZY, Zhu BY, et al. Effects of sertraline on executive function following functional magnetic resonance imaging fMRI-activation modulated arc therapy, and three-dimensional conformal radiotherapy and the results of helical tomotherapy tomotherapy. BioMed Res Int 2018;2018:9153496.
[31] Kennedy WR, Thomas MA, Stanley JA, et al. Single-institution phase 1/2 prospective clinical trial of single-fraction, high-gradient adjuvant partial-breast irradiation for hormone sensitive stage 0-i breast cancer. Int J Radiat Oncol Biol Phys 2020;107:344–52.

[32] Johnstone PAS, Alla R, Yu HM, et al. Patient-reported outcomes: using ESAS to screen for anemia. Support Care Cancer 2019;28:4141–5.

[33] de Kock I, Mirhosseini M, Lau F, et al. Conversion of Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group Performance Status (ECOG) to Palliative Performance Scale (PPS), and the interchangeability of PPS and KPS in prognostic tools. J Palliat Care 2013;29:163–9.

[34] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 2011;343:d5928.

[35] Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ (Clin Res ed) 2004;328:1490.

[36] Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011;64:380–2.

[37] Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 1. 2015. J Natl Compr Canc Netw 2014;12:1738–61.

[38] Jimenez G, Tan WS, Virk AK, et al. Overview of systematic reviews of advance care planning; summary of evidence and global lessons. J Pain Symptom Manage 2018;56:436–59. e425.